Biotage

Transaction in Own Shares • Apr 28, 2017

Contact persons: SE-751 03 Uppsala Torben Jörgensen, CEO Tel:018 56 59 00 Tel: 0707-49 05 84, torben.jorgensen@biotage.com www.biotage.com

Box 8

Uppsala April 28, 2017

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting's resolution to authorize the board to decide on the acquisition and sale of the company's own shares.

At the Annual General Meeting held on 27 April 2017, the board was authorized to decide on the acquisition and sale of the company's own shares up and until the forthcoming Annual General Meeting. The shares acquired may not exceed 10 per cent of the total number of outstanding Biotage shares at any time. The purpose of the repurchase program is to give the board a wider freedom of action in the work with the company's capital structure and thereby improve shareholder value. Acquisition and sale of shares will take place on the NASDAQ OMX Stockholm at a price within the price interval at any time recorded. Biotage currently does not own any own shares.

This information is information that Biotage AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on April 28, 2017.

About Biotage

Biotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage's products are used by government authorities, academic institutions, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan and South Korea. Biotage has approx. 300 employees and had sales of 667 MSEK in 2016. Biotage is listed on the NASDAQ OMX Nordic. Website: www.biotage.com